Transition by patient status and next supply need, not by sending every prescription to a new destination at once. Clinical decisions, prescription changes and operational reconciliation need separate owners.
Proposed transition sequence:
- Map the population: current product, presentation, state, last fill, expected next need and unresolved order status.
- Verify the destination: permissions, product acceptance, capacity and payment route.
- Assign clinical review: formulation, medicine or regimen changes go to the prescriber.
- Reconcile existing orders: distinguish prescriptions awaiting action, paid orders, shipped parcels, refunds and unused refills.
- Communicate costs and actions: tell patients who will contact them and what they must do.
- Pilot a bounded cohort: include both straightforward and exception-prone workflows.
- Expand only after reconciliation: confirm receipt and resolve duplicate billing or shipment risks.
- Retain transition support: do not terminate access to necessary records prematurely.
Lilly’s FAQ states that changes in medicine, dose or formulation require a new prescription in its workflow. Do not treat a pharmacy migration as permission for an administrative product substitution. (lilly.com)
Define stop conditions before launch: unexplained concentration differences, unresolved permissions, missing instructions or untraceable orders should halt the affected transition.
Sources cited on this page
- lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/faq